Clinical-oncological status of patients included in RANIDO clinical trial treated with Racotumomab or Nimotuzumab

Abstract

Introduction: RANIDO is a clinical trial extended to primary health care with the objective of assessing the efficiency of Cuban biotechnology products Racotumomab and Nimotuzumab for the treatment of non-small cell lung cancer. Objective: to characterize the patients from the clinical and oncological assessments included in the RANIDO clinical trial treated with Racotumomab and Nimotuzumab in Pinar del Río between January 2013 and January 2018. Methods: observational, descriptive and cross-sectional study carried out at Raúl Sánchez Rodríguez University Polyclinic between 2013 and 2018. The target group comprised 33 patients, working with the totality of them. The information was collected from the clinical records. Descriptive statistical methods were applied. Results: male patients prevailed (63,6 %). The age group from 60 to 69 years old predominated (57,6 %). Adenocarcinoma (54,5 %) was the predominant histopathological type. Stage IIIB was the most frequent at diagnosis (54,5 %); the disease in progression was the response to the standard oncological treatment (48.5 %). Most patients survived between 12-17 months (42,4%); the overall survival rate was 18,6 months. Conclusions: a greater number of adults were found after the sixth decade of life and of the male sex; who were affected in greater percentage by epidermoid carcinoma and detected in advanced stages of the disease. With the immunotherapy, favorable results were obtained in the treatment of patients with advanced stages of the disease, which turned into an increase in their survival.

Keywords

• neoplasias pulmonares
• carcinoma de pulmón de células no pequeñas
• ensayo clínico.